Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 1, 2026, PTC Therapeutics, Inc. (PTCT) has a Wall Street consensus price target of $84.50, based on estimates from 26 covering analysts. With the stock currently trading at $68.19, this represents a potential upside of +23.9%. The company has a market capitalization of $5.45B.
Analyst price targets range from a low of $50.00 to a high of $120.00, representing a 83% spread in expectations. The median target of $84.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 16 analysts rating the stock as a Buy or Strong Buy,8 rating it Hold, and 2 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, PTCT trades at a trailing P/E of 8.8x. Analysts expect EPS to grow -108.6% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $126.95, with bear and bull scenarios of $-322.43 and $188.62 respectively. Model confidence stands at 32/100, suggesting limited visibility into future performance.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how PTCT stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for PTCT is $84.5, representing 23.9% upside from the current price of $68.19. With 26 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
PTCT has a consensus rating of "Buy" based on 26 Wall Street analysts. The rating breakdown is predominantly bullish, with 16 Buy/Strong Buy ratings. The consensus 12-month price target of $84.5 implies 23.9% upside from current levels.
PTCT's current price is $68.19 with a consensus target of $84.5 (23.9% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $120 for PTCT, while the most conservative target is $50. The consensus of $84.5 represents the median expectation. Our quantitative valuation model projects a bull case target of $189 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
PTCT is heavily covered by Wall Street, with 26 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 16 have Buy ratings, 8 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month PTCT stock forecast based on 26 Wall Street analysts shows a consensus price target of $84.5, with estimates ranging from $50 (bear case) to $120 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $127, with bear/bull scenarios of $-322/$189.
Our quantitative valuation model calculates PTCT's fair value at $127 (base case), with a bear case of $-322 and bull case of $189. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 32/100.
Wall Street analysts are very optimistic on PTCT, with a "Buy" consensus rating and $84.5 price target (23.9% upside). 16 of 26 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
PTCT analyst price targets range from $50 to $120, a 83% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $84.5 consensus represents the middle ground. Our model's $-322-$189 range provides an independent fundamental perspective.